|
|
|
|
|
|
|
|
|
|
|
|
|
05.11.25 - 13:03
|
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
|
|
|
Achieved $47.2 million in RYTELO® net product revenue in Q3 2025
Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis
Strengthened leadership team with appointment of Chief Commercial Officer and additional key executives
Announced one oral and four poster presentations accepted at the American Society of Hematology (ASH) 2025 Annual Meeting
Company to host conference call and webcast today, November 5, at 8:00 a.m. ET
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2025 and recent business highlights.
"The high unmet need in lower-risk MDS is well known, and RYTELO is a therapy with a novel mechanism of action and the potential to significantly impact the treatment paradigm. There is work ahead of us to fully maximize the value of this therapy and...
|
|
|
03.11.25 - 15:06
|
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies (Business Wire)
|
|
|
New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS
Additional poster presentations include long-term survival outcomes, translational biomarker analyses, and an update on combination therapy trial in myelofibrosisFOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts – one oral and four poster presentations – have been accepted for presentation at the 67th American Society of Hematology (ASH) 2025 Annual Meeting, to be held December 6-9, 2025 in Orlando, FL. The data feature new clinical and translational analyses of RYTELO (imetelstat) across lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) and myelofibrosis (MF).
“The ASH 2025 presentations reflect growing scientific momentum around imetelstat and telomeras...
|
|
|
27.10.25 - 13:03
|
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company aiming to change lives by changing the course of cancer, today announced that it will release its third quarter financial results and business highlights before the market opens on Wednesday, November 5, 2025 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live webcast of the conference call and related presentation will be available on the Company's website at www.geron.com/investors/events. An archive of the webcast will be available on the Company's website.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myel...
|
|
|
20.10.25 - 23:33
|
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--$GERN--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock, consisting of stock options to purchase an aggregate of 1,553,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 26,500 shares of common stock, to three newly hired employees and (ii) October 20, 2025, covering an aggregate of 1,500,000 shares of its common stock to one newly hired employee, each as an inducement material to their acceptance of employment with Geron.
The stock options granted on October 17, 2025 have an exercise price of $1.20 per share and the stock options granted on October 20, 2025 have an exercise price of $1.27 per share, in each case which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares...
|
|
|
|
|
|
|
|
|
18.09.25 - 22:03
|
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 shares of its common stock, consisting of stock options to purchase an aggregate of 644,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 322,000 shares of common stock, to sixteen newly hired employees as an inducement material to their acceptance of employment with Geron....
|
|
|
|
|
18.08.25 - 22:06
|
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 shares of its common stock, consisting of stock options to purchase an aggregate of 348,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 174,000 shares of common stock, to eleven newly hired employees as an inducement material to their acceptance of employment with Geron.
The stock options and RSUs were granted on August 15, 2025. The stock options have an exercise price of $1.45 per share, which is equal to the closing price of Geron common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of each employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued ...
|
|
|
08.08.25 - 22:06
|
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron's new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron.
The stock options were granted on August 7, 2025. The stock options have an exercise price of $1.30 per share, which is equal to the closing price of Geron common stock on the grant date and have a ten-year term. 7,000,000 of the stock options vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of his employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. 4,000,000 of the stock options vest over four years, with 25% of t...
|
|
|
|
|
|
|
|
|
06.08.25 - 13:18
|
Geron Appoints Harout Semerjian as President and Chief Executive Officer (Business Wire)
|
|
|
Industry veteran brings 30+ years of commercial hematology and oncology experience to help accelerate Geron's next phase of growthFOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective tomorrow.
Mr. Semerjian will succeed Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Ms. Bir will continue in her role on Geron's Board of Directors, where she will contribute her insight and strategic counsel.
“Our Board conducted an extensive search to identify a leader with deep commercial and hematology expertise, global perspective, and a steadfast commitment to improving patient lives,” said Elizabeth O'Farrell, Chairman of Geron's Board of Directors. “Harout brings over 30 years of commercial experience acro...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
